Dostarlimab TSR-042|cas:2022215-59-2|西域试剂

Dostarlimab TSR-042

产品编号：Bellancom-P99345| CAS NO：2022215-59-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99345		￥4000.00	杭州北京（现货）
Bellancom-P99345		￥10400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Dostarlimab TSR-042

产品介绍

Dostarlimab (TSR-042) 是一种人源化抗 PD-1 单克隆抗体。Dostarlimab 与人 PD-1 具有高亲和力，并竞争性地抑制其与其配体 PD-L1 和 PD-L2 的相互作用，IC₅₀s 分别为 1.8 nM 和 1.5 nM。

生物活性

Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively.

体外研究

Dostarlimab (10-10000 ng/mL) 以剂量依赖的方式与人和食蟹猴 CD3⁺ T 细胞上表达的原生 PD-1 受体结合。
Dostarlimab (0-375 nM; 48 h) 在人 CD4⁺ T 细胞 MLR 实验中增加 IL-2 的产生，EC₅₀ 大约为 1 nM，在葡萄球菌肠毒素 B (SEB) 刺激的 PBMC 细胞中增加 IL-2 的产生，EC₅₀ 大约为 0.1 nM，增强干扰素 (IFN)-γ 的释放，EC₅₀ 大约为 0.5 nM。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Dostarlimab (200 µg/mouse; i.p.; twice weekly for 35 days) 在人源化小鼠模型中显示出抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized NOG-EXL mice, A549 and MDA-MB-436 tumor model
Dosage:	200 µg/mouse
Administration:	Intraperitoneal injection; twice weekly for 35 days
Result:	Resulted in great inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination). The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor-infiltrating CD8⁺ T cells. Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%).

体内研究

Dostarlimab (200 µg/mouse; i.p.; twice weekly for 35 days) 在人源化小鼠模型中显示出抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized NOG-EXL mice, A549 and MDA-MB-436 tumor model
Dosage:	200 µg/mouse
Administration:	Intraperitoneal injection; twice weekly for 35 days
Result:	Resulted in great inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination). The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor-infiltrating CD8⁺ T cells. Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%).